J. Donahue to Aged
This is a "connection" page, showing publications J. Donahue has written about Aged.
Connection Strength
0.116
-
Tandri H, Griffith LS, Tang T, Nasir K, Zardkoohi O, Reddy CV, Capps M, Calkins H, Donahue JK. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. Heart Rhythm. 2006 Jul; 3(7):762-8.
Score: 0.021
-
Henrikson CA, Brinker JA, Donahue JK. Temporary placement of a defibrillating lead in the treatment of infection and ventricular tachycardia. Heart Rhythm. 2006 Feb; 3(2):222-4.
Score: 0.021
-
Eldadah ZA, Donahue JK. Successful implantable cardioverter defibrillator placement in an ambulatory patient without thoracic venous access. J Cardiovasc Electrophysiol. 2004 Jun; 15(6):716-8.
Score: 0.019
-
Vaze A, Tran KV, Tanriverdi K, Sardana M, Lessard D, Donahue JK, Barton B, Aurigemma G, Lubitz SA, Lin H, Nasr GH, Mandapati A, Benjamin EJ, Vasan RS, Freedman JE, McManus DD. Relations between plasma microRNAs, echocardiographic markers of atrial remodeling, and atrial fibrillation: Data from the Framingham Offspring study. PLoS One. 2020; 15(8):e0236960.
Score: 0.015
-
Sardana M, Ogunsua AA, Spring M, Shaikh A, Asamoah O, Stokken G, Browning C, Ennis C, Donahue JK, Rosenthal LS, Floyd KC, Aurigemma GP, Parikh NI, McManus DD. Association of Left Atrial Function Index With Late Atrial Fibrillation Recurrence after Catheter Ablation. J Cardiovasc Electrophysiol. 2016 12; 27(12):1411-1419.
Score: 0.011
-
Shaikh AY, Esa N, Martin-Doyle W, Kinno M, Nieto I, Floyd KC, Browning C, Ennis C, Donahue JK, Rosenthal LS, McManus DD. Addition of B-Type Natriuretic Peptide to Existing Clinical Risk Scores Enhances Identification of Patients at Risk for Atrial Fibrillation Recurrence After Pulmonary Vein Isolation. Crit Pathw Cardiol. 2015 Dec; 14(4):157-65.
Score: 0.010
-
McManus DD, Tanriverdi K, Lin H, Esa N, Kinno M, Mandapati D, Tam S, Okike ON, Ellinor PT, Keaney JF, Donahue JK, Benjamin EJ, Freedman JE. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Heart Rhythm. 2015 Jan; 12(1):3-10.
Score: 0.010
-
Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013 Jan 14; 14:7.
Score: 0.009